@Article{Nieder2026,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
year="2026",
title="Reirradiation and teclistamab
in relapsed multiple myeloma:
initial experience in two heavily
pretreated patients with extensive
disease",
abstract=" This  article is aimed to report our initial experience with the\ bispecific  T-cell engager teclistamab administered with concomitant  radiotherapy, including reirradiation, in two patients with  widespread multiple myeloma, including hepatic and meningeal relapse,  respectively. This is a\ retrospective patient record assessment  at a\ single institution. Both patients had previously received  several lines of\ systemic therapy and radiotherapy to multiple  target volumes, resulting in a\ considerable cumulative bone  marrow dose when completing their recent courses in 2025. The\ Patient  1 started current radiotherapy with already compromised blood cell  counts, while the\ Patient 2 had preserved values, except for  lymphocytes. Both patients rapidly developed grade IV haematological  toxicity (white blood cells and platelets) but recovered within few  weeks. Radiotherapy did not cause other acute toxicity greater than  grade II. Given the\ serious haematological toxicity observed in  our patients, hospitalization and close monitoring by a\ dedicated  team of\ experienced haematologists may become necessary in  complex settings like those described here. Their expertise might  also be required to manage cytokine release syndrome and potentially  life-threatening neutropenic infections. ",
author="Nieder, Carsten
and Hansen, Siri
and Solhaug, Terje
and Hallstensen, Randi",
doi="10.5114/wo.2026.162045",
url="http://dx.doi.org/10.5114/wo.2026.162045"
}